Canaccord analyst Sumant Kulkarni raised the firm’s price target on Stoke Therapeutics to $21 from $18 and keeps a Buy rating on the shares. The firm noted they announced very promising Phase 1/2a data from two open-label Phase 1/2a and two open-label extension (OLE) studies of STK-001 for Dravet syndrome. The data takes their probability of approval to 33% from 25%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK: